VRTX's logo.
Ticker Symbol: VRTX

Vertex Pharmaceuticals, Inc.

$188.33 - 20-12-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0000875320

Company Profile

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 50 Northern Ave
Website: www.vrtx.com
CEO: Jeffrey Leiden
Tags:
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $345.15
Change: -$2.68 ( -0.77%)
Days Range: $341.85 - $347.79
Beta: 0.48
52wk. High: $375.93
52wk. Low: $282.20
Ytd. Change 19.68%
50 Day Moving Average: $354.72
200 Day Moving Average: $345.77
Shares Outstanding: 258094815

Valuation

Market Cap: 8.9T
PE Ratio: 26.67
EPS (TTM): 12.94

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A